Cardiff Oncology is a San Diego biotechnology company developing onvansertib, an oral drug for several cancers. CRDF reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 25 | Craig-Hallum | Initiated | Buy | |
| Sep 15 | HC Wainwright & Co. | Upgrade | Buy | |
| Jun 3 | Craig-Hallum | Downgrade | Hold |
Seasonality
How CRDF has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in CRDF in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRDF is in one of them and how their past CRDF trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CRDF in an article yet. Here's the latest on the wider market.
About Cardiff Oncology
Cardiff Oncology is a biotechnology company based in San Diego, California, that develops cancer treatments. Its lead candidate, onvansertib, is an oral drug designed to block the PLK1 enzyme, and it is tested alone and alongside standard cancer therapies. The company is running studies in colorectal, pancreatic, lung, breast and blood cancers, focusing on patients whose tumors carry certain genetic markers.
- Headquarters
- San Diego, CA